三生制药与辉瑞达成重磅授权交易,释放PD-1/VEGF的同类最佳潜力

招银国际
21 May

一、交易背景与规模三生制药(1530HK)与辉瑞达成了一项重磅授权交易,将公司研发的PD-1/VEGF双抗药物707的全球权益(除中国内地外)授权给辉瑞。此次交易包括12.5亿美元的首付款和最高达48亿美元的里程碑付款,并且三生制药还将获得双位数的产品销售分成。此外,辉瑞还将在协议生效日认购价值1亿美元的三生制药普通股。此次交易规模远超市场预期,显示了辉瑞对707潜力的高度认可。二、707的临床...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10